Atlas of Genetics and Cytogenetics in Oncology and Haematology


Home   Genes   Leukemias   Solid Tumors   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

X Y 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 NA

t(6;8)(p21;q24) MYC/SUPT3H

Written2018-05Muntadhar Al Moosawi, Hélène Bruyère
Hematopathology, Department of Pathology and Laboratory Medicine, muntadhar.almoosawi@vch.ca (MAM); Vancouver General Hospital Cytogenetics Laboratory, Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada, helene.bruyere@vch.ca (HB)

Abstract Review on t(6;8)(p21;q24), with data on clinics, and the genes involved.

Keywords Blastic, plasmacytoid, dendritic, cell, neoplasm, t(6;8), chromosome 6, chromosome 8

(Note : for Links provided by Atlas : click)

Identity

ICD-Topo C420,C421,C424
ICD-Morpho 9727/3 Blastic plasmacytoid dendritic cell neoplasm
Atlas_Id 2987
 
  Figure 1: t(6;8)(p21.1;q24.2), G-banding. Courtesy Hélène Bruyère.

Clinics and Pathology

Disease Blastic plasmacytoid dendritic cell neoplasm (BPDCN)
Phenotype / cell stem origin Disease derives from precursors of plasmacytoid dendritic cells.
Epidemiology The t(6;8) has been found in a limited subset of BPDCN: Less than 10 cases reported to date. Preponderance of male cases (7/8 to date). Average age 65 years, in keeping with BPDCN's mean/median age of 61-67 (WHO Classification of Tumours of Hematopoietic and Lymphoid Tissues, 2017).
Clinics In general, BPDCN is an aggressive disease that most commonly involves the skin but can also infiltrate the bone marrow and peripheral blood as well as the lymph nodes. Seven out of eight cases of t(6;8) reported so far had bone marrow involvement based on bone marrow biopsy (Boddu et al., 2018; Momoi et al., 2002; Takiuchi et al., 2012; Nakamura et al., 2015; Fu et al., 2013; personal communication). One case reported by Leroux et al. in 2002 showed an extensive peripheral blood involvement with 95% circulating blasts. Although a bone marrow biopsy was not performed, the heavy involvement of peripheral blood, indicating bone marrow involvement, was sufficient to make the diagnosis.
Cytogenetics Found with additional abnormalities in all cases, as the sole abnormality in the stemline in one case (Boddu et al., 2018), as a secondary abnormality in one case (Boddu et al., 2018), as part of a complex karyotype in 5/8 cases.
Table 1: Cases of BPDCN with t(6;8)(q21;q24)
ReferenceAgeSexSite involvedKaryotype
Momoi et al. 200269MBM, Skin46, XY, add(5)(q11), add(5)(q31), t(6;8)(p21,q24),del(13)(q12q14),add(15)(q13)
Boddu et al. 201860MBM, Skin, LN46,XY,del(13)(q12q22)[16]/46,idem,t(6;8)(p21;q24.1),del(14)(q24q32)[2]/46,idem,t(6;8)(p21;q24.1),del(14)(q24q32)[cp2]
Boddu et al. 201871MBM, Skin 46,XY,t(6;8)(p21;q24.2)[5]/47,idem,+18[11]/46,XY[4]
Takiuchi  et al. 201274MBM, spleen47, XY, t(6;8)(p21;q24),+r
Nakamura et al. 201581MBM, Skin, LN47,X,-Y t(6;8)(p21;q24),+add(7)(p11.2),+der(8)t(6;8),+20[17/20], 46,XY[3/20] among LN cells; 48,X,Y,t(6;8)(p21;q24),+add(7)(p11.2),+der(8)t(6;8),+2[5/13],49,idem,+mar1[2/13],49,idem,der(8)t(6;8),?t(9;15)(p22;q15),+mar1 2/13]/46, XY[3/13]
Fu et al. 2013 67FBM, LN46,XX,del(5)(q13q33),t(6;8)(p21;q24)
Leroux et al. 200274MPB (BM not performed)49,XY,+add(6)(q21),-8,+2mar,+r[6]/49,idem,t(15;16)(?q21;?q21)[6]/49,idem,t(3;5)(?q21;?q31)[5], ish wcp M-FISH 49,XY,+6,t(6;8)(p21;q24),+r(12),+20/49,idem,inv(15)(q1?4q2?3),t(16;16)(q?;q?)/49,idem,t(3;5)(q?21;q?31)[13]
Personal communication29MBM, PB44-45,X,-Y,del(1)(p12p22),t(6;8)(p21.1;q24.2)[cp5]/46,XY[1].nuc ish(MYCx2)(5'MYC sep 3'MYCx1)[54/100]

BM: bone marrow, LN: lymph node, PB: peripheral blood.
Of note, cytogenetic abnormalities are present in about two-thirds of BPDCN cases, involving chromosomes 5q34, 12p13, 13q13-21, 15q, and loss of chromosome 9 (WHO Classification of Tumours of hematopoietic and lymphoid tissues, 2017).
Prognosis The prognosis of BPDCN is usually poor in adults (Bekkenk et al., 2004, Suzuki et al., 2005) and this appears to be true for cases with t(6;8). Two cases with this translocation failed to respond to treatment, the overall survival being 3 and 12 months respectively (Boddu et al., 2018). One patient relapsed three months after the initial diagnosis and treatment and received multiple lines of chemotherapy but eventually died because of septic shock nine months after the initial diagnosis (Momoi et al., 2002). The only female reported so far with t(6;8) received palliative chemotherapy and died two months after the initial diagnosis. Another patient responded to treatment and tumor cells in the peripheral blood disappeared in day 8; however, the patient died of septic shock on day 16 (Takiuchi et al., 2012). A 29-year-old male patient who was diagnosed with BPDCN with complex karyotype including t(6;8) received ALL-based chemotherapy achieved complete morphological remission by day 24 of treatment and has been on sustained remission at least until this paper was written (personal communication).

Cytogenetics

Note The t(6;8)(p21.1;q24.2) is identified by conventional karyotyping.
Note: Other translocations involving 8q24 have been reported in BPDCN: t(8;14)(q24;q32), t(X;8)(q24;q24), t(3;8)(p25;q24) (Boddu et al., 2018; Nakamura et al., 2015)
 
  Figure 2: FISH image showing the presence of a normal (fused) MYC signal and separated 5'MYC signal from 3'MYC signal.
 
  Figure 3: Image from immunohistochemistry with MYC antibody on bone marrow cells.

Genes involved and Proteins

Gene NameMYC
Location 14q23.3
Dna / Rna DNA/RNA: CMYC is composed of three exons spanning over 4 kb with the second and third exons encoding most MYC protein.
Gene NameSUPT3H
Location 6p21.1
Dna / Rna DNA/RNA: SUPT3H is composed of 22 exons with a size of 570 kb.
Protein 399 amino acids and 44 kDa.

Result of the chromosomal anomaly

Hybrid gene
Description The translocation has been shown to result in a split MYC signal when using a commercial MYC break-apart FISH probe (Nakamura et al., 2015, Boddu et al., 2018, Fu et al., 2013). Involvement of the MYC gene has also be inferred from the positive MYC immunochemistry observed on bone marrow slides (Nakamura et al., 2015, Boddu et al., 2018). Molecular analysis of the 8q24 breakpoint showed that it occurred in the PVT1 gene on chromosome 8 (Nakamura et al., 2015; Fu et al., 2013; Jardin et al., 2009). PVT1 is located 149 kb telomeric to MYC. It is a long non-coding RNA located within the interval between the 5' MYC probe and 3'MYC commercial probes used to identify MYC rearrangements. Jardin et al. in 2009 found, in BPDCN, a 5.6-Mb interstitial deletion on 8q24 involving PVT1 bringing MYC oncogene adjacent to miR-30b/30c leading to possible up-regulation of these genes.
  

To be noted

Additional cases are needed to delineate the epidemiology of this rare entity:
you are welcome to submit a paper to our new Case Report section.

Bibliography

Classification and clinical behaviour of blastic plasmacytoid dendritic cell neoplasms according to their maturation-associated immunophenotypic profile.
Martèn-Martèn L, López A, Vidriales B, Caballero M. D, Rodrigues A. S, Ferreira S. I, Lima M, Almeida S, Valverde B, Martènez P, Ferrer A, Candeias J, Ruèz-Cabello F, Buadesa J. M, Sempere A, Villamor N, Orfao A, and Almeida J
Oncotarget. 6:19204-16.
PMID 26056082
 
Cutaneous lymphoblastic lymphoma of putative plasmacytoid dendritic cell-precursor origin: two cases
Momoi A, Toba K, Kawai K, Tsuchiyama J, Suzuki N, Yano T, Uesugi Y, Takahashi M, Aizawa Y
Leuk. Res. 26 (7) (2002) 693-698.
PMID 12008089
 
Identification of SUPT3H as a novel 8q24/MYC partner in blastic plasmacytoid dendritic cell neoplasm with t(6;8)(p21;q24) translocation
Nakamura Y, Kayano H, Kakegawa E, Miyazaki H, Nagai T, Uchida Y, Ito Y, Wakimoto N, Mori S, Bessho M
Blood Cancer J 2015 Apr 10;5:e301
PMID 25860292
 
Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: an Italian multicenter study.
Pagano L, Valentini CG, Pulsoni A, Fisogni S, Carluccio P, Mannelli F, Lunghi M, Pica G, Onida F, Cattaneo C, Piccaluga PP, Di Bona E, Todisco E, Musto P, Spadea A, D'Arco A, Pileri S, Leone G, Amadori S, Facchetti F; GIMEMA-ALWP (Gruppo Italiano Malattie EMatologiche dell'Adulto, Acute Leukemia Working Party).
Haematologica. 2013 Feb;98(2):239-46
PMID 23065521
 
Blastic natural killer cell lymphoma/leukemia (CD56-positive blastic tumor): prognostication and categorization according to anatomic sites of involvement.
Suzuki R, Nakamura S, Suzumiya J, Ichimura K, Ichikawa M, Ogata K, Kura Y, Aikawa K, Teshima H, Sako M, Kojima H, Nishio M, Yoshino T, Sugimori H, Kawa K, Oshimi K; NK-cell Tumor Study Group.
Cancer. 2005 Sep 1;104(5):1022-31.
PMID 15999368
 
Leukemic manifestation of blastic plasmacytoid dendritic cell neoplasm lacking skin lesion: a borderline case between acute monocytic leukemia
Takiuchi Y, Maruoka H, Aoki K, et al.,
J. Clin. Exp. Hematopathol. 2012 52(2):107-111.
 
Alterations of the cell-cycle inhibitors p27(KIP1) and p16(INK4a) are frequent in blastic plasmacytoid dendritic cell neoplasms.
Wiesner T, Obenauf AC, Cota C, Fried I, Speicher MR, Cerroni L.
J Invest Dermatol. 2010 Apr;130(4):1152-7
PMID 19924135
 

Citation

This paper should be referenced as such :
Al Moosawi M, Bruyère H
t(6;8)(p21;q24) MYC/SUPT3H;
Atlas Genet Cytogenet Oncol Haematol. in press
On line version : http://AtlasGeneticsOncology.org/Anomalies/t0608p21q24SUPT3H-MYCID2987.html


Translocations implicated (Data extracted from papers in the Atlas)

 t(6;8)(p21;q24) MYC/SUPT3H

External links

Mitelman databaset(6;8)(p21;q24) [Case List]    t(6;8)(p21;q24) [Transloc-MCList] MYC/SUPT3H [Fusion-MCList]
arrayMap (UZH-SIB Zurich)Morph ( 9727/3) -   [auto + random 100 samples .. if exist ]   [tabulated segments]
 
 
REVIEW articlesautomatic search in PubMed
Last year articlesautomatic search in PubMed
All articlesautomatic search in PubMed


© Atlas of Genetics and Cytogenetics in Oncology and Haematology
indexed on : Fri Jun 22 17:41:08 CEST 2018


Home   Genes   Leukemias   Solid Tumors   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

For comments and suggestions or contributions, please contact us

jlhuret@AtlasGeneticsOncology.org.